“Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy”, Dermatol Reports, Jul. 2025, doi: 10.4081/dr.2025.10315.